BRANFORD, Conn., April 28, 2026--(BUSINESS WIRE)--Quantum-Si Incorporated (Nasdaq: QSI) ("Quantum-Si," "QSI" or the "Company"), a proteomics company redefining protein analysis through single-molecule ...
"We delivered a strong quarter of Proteus execution, achieving the key development milestones we outlined at our Investor & Analyst Day in November 2025. Most notably, we achieved automated sequencing ...
Hosted on MSN
Quantum-Si Q1 earnings call highlights
Quantum-Si (NASDAQ:QSI) reported first-quarter 2026 revenue of $258,000 and reiterated that the year will be a transition period focused on development and market preparation for its next-generation ...
Quantum‑Si’s latest earnings call conveyed a cautiously optimistic tone as management highlighted technical wins and scientific validation alongside sobering near‑term financial realities. Executives ...
BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, and ...
Quantum-Si earnings call balanced cautious optimism with clear execution risk as management highlighted major technical progress on its Proteus protein sequencing platform while acknowledging minimal ...
Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics company redefining protein analysis through single-molecule protein sequencing, today announced that the ...
Successful sequencing on integrated Proteus™ instruments Sequenced first customer samples on a Proteus prototype system Current developmental sequencing kit detects 17 amino acids Multiple customer ...
BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics technology company redefining ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results